IN2014MN00948A - - Google Patents
Info
- Publication number
- IN2014MN00948A IN2014MN00948A IN948MUN2014A IN2014MN00948A IN 2014MN00948 A IN2014MN00948 A IN 2014MN00948A IN 948MUN2014 A IN948MUN2014 A IN 948MUN2014A IN 2014MN00948 A IN2014MN00948 A IN 2014MN00948A
- Authority
- IN
- India
- Prior art keywords
- compounds
- cancer
- diseases
- processes
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
The invention relates to new pyridopyrazine derivative compounds to pharmaceutical compositions comprising said compounds to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases e.g. cancer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552888P | 2011-10-28 | 2011-10-28 | |
GBGB1118656.6A GB201118656D0 (en) | 2011-10-28 | 2011-10-28 | New compounds |
PCT/GB2012/052672 WO2013061080A1 (en) | 2011-10-28 | 2012-10-26 | Anticancer pyridopyrazines via the inhibition of fgfr kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN00948A true IN2014MN00948A (en) | 2015-04-24 |
Family
ID=45373584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN948MUN2014 IN2014MN00948A (en) | 2011-10-28 | 2012-10-26 |
Country Status (32)
Country | Link |
---|---|
US (2) | US9309242B2 (en) |
EP (1) | EP2776435B1 (en) |
JP (1) | JP6169583B2 (en) |
KR (1) | KR102066496B1 (en) |
CN (1) | CN104011051B (en) |
AP (1) | AP4060A (en) |
AR (1) | AR088567A1 (en) |
AU (1) | AU2012328170B2 (en) |
BR (1) | BR112014010206B8 (en) |
CA (1) | CA2853390C (en) |
CL (1) | CL2014001065A1 (en) |
CO (1) | CO6940422A2 (en) |
CR (1) | CR20140190A (en) |
DK (1) | DK2776435T3 (en) |
EA (1) | EA027563B1 (en) |
EC (1) | ECSP14013325A (en) |
ES (1) | ES2688868T3 (en) |
GB (1) | GB201118656D0 (en) |
HR (1) | HRP20181533T1 (en) |
IL (1) | IL232083B (en) |
IN (1) | IN2014MN00948A (en) |
JO (1) | JO3419B1 (en) |
LT (1) | LT2776435T (en) |
MX (1) | MX353654B (en) |
MY (1) | MY185666A (en) |
NI (1) | NI201400032A (en) |
SG (1) | SG11201401055XA (en) |
SI (1) | SI2776435T1 (en) |
TW (1) | TWI602814B (en) |
UA (1) | UA111386C2 (en) |
UY (1) | UY34418A (en) |
WO (1) | WO2013061080A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
AR094812A1 (en) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
AU2014338549B2 (en) | 2013-10-25 | 2017-05-25 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors |
AR098145A1 (en) * | 2013-10-25 | 2016-05-04 | Novartis Ag | COMPOUNDS DERIVED FROM BICYCLIC PIRIDYL FUSED AS INHIBITORS OF FGFR4 |
RU2715893C2 (en) * | 2014-03-26 | 2020-03-04 | Астекс Терапьютикс Лтд | Combination of inhibitor fgfr and inhibitor igf1r |
JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
HUE053654T2 (en) * | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | Combinations of fgfr- and cmet-inhibitors for the treatment of cancer |
KR102344105B1 (en) | 2014-08-18 | 2021-12-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Salt of monocyclic pyridine derivative and crystal thereof |
US20180185341A1 (en) | 2014-10-03 | 2018-07-05 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
TWI695837B (en) | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | A triazolopyridazine as a kinase modulator |
JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US9802917B2 (en) * | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
SI3353177T1 (en) | 2015-09-23 | 2020-08-31 | Janssen Pharmaceutica Nv | Tricyclic heterocycles for the treatment of cancer |
EP3353164B1 (en) | 2015-09-23 | 2021-11-03 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
EP3365335B1 (en) | 2015-10-23 | 2024-02-14 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
WO2017164705A1 (en) * | 2016-03-24 | 2017-09-28 | 재단법인 대구경북첨단의료산업진흥재단 | Novel pyridine derivative, method for preparing same, and pharmaceutical composition for preventing or treating fgfr-related disease containing same as active component |
JP7088906B2 (en) * | 2016-08-12 | 2022-06-21 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | FGFR4 inhibitor and its production method and use |
CN108101857B (en) * | 2016-11-24 | 2021-09-03 | 韶远科技(上海)有限公司 | Scalable process for preparing 2-amino-3-bromo-6-chloropyrazine |
CN108264510A (en) * | 2017-01-02 | 2018-07-10 | 上海喆邺生物科技有限公司 | A kind of selective depression kinases compound and application thereof |
EP3777860A4 (en) | 2018-03-28 | 2021-12-15 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
EP4085055A1 (en) | 2019-12-30 | 2022-11-09 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
WO2021146163A1 (en) * | 2020-01-17 | 2021-07-22 | Beta Pharma, Inc. | Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitors |
CA3205986A1 (en) | 2020-12-30 | 2022-07-07 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
JP2024509795A (en) | 2021-02-26 | 2024-03-05 | タイラ・バイオサイエンシーズ・インコーポレイテッド | Aminopyrimidine compounds and their usage |
WO2024006897A1 (en) | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Indazole compounds |
WO2024006883A1 (en) | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
GB9125001D0 (en) | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds |
EP0698015A1 (en) | 1993-05-14 | 1996-02-28 | Genentech, Inc. | Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
US5882864A (en) | 1995-07-31 | 1999-03-16 | Urocor Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
AU751188C (en) | 1997-05-28 | 2005-06-30 | Aventis Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
UA71555C2 (en) * | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
EP1147094A1 (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
SK3542002A3 (en) | 1999-09-15 | 2003-04-01 | Warner Lambert Co | Pteridinones as kinase inhibitors |
DE10013318A1 (en) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Quinoxaline derivatives are used as photo-stable UV filters in cosmetic or pharmaceutical sunscreens for the hair or skin |
WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
WO2003051833A2 (en) | 2001-12-18 | 2003-06-26 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
HU229477B1 (en) | 2001-12-24 | 2014-01-28 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
JP2003213463A (en) | 2002-01-17 | 2003-07-30 | Sumitomo Chem Co Ltd | Metal anticorrosive and cleaning solution |
JP4394960B2 (en) | 2002-04-08 | 2010-01-06 | メルク エンド カムパニー インコーポレーテッド | Akt activity inhibitor |
US7074534B2 (en) | 2002-07-10 | 2006-07-11 | E. I. Du Pont De Nemours And Company | Polymeric charge transport compositions and electronic devices made with such compositions |
US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
JP4560483B2 (en) | 2002-10-03 | 2010-10-13 | ターゲジェン インコーポレーティッド | Angiogenic substances and methods for their use |
AR043059A1 (en) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS |
US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
DE602004021558D1 (en) | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION |
EP1620413A2 (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
BRPI0410348A (en) | 2003-05-14 | 2006-05-30 | Torreypines Therapeutics Inc | compounds and uses thereof in amyloid-beta modulation |
DE10323345A1 (en) * | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | New pyridopyrazines and their use as kinase inhibitors |
MXPA05012645A (en) * | 2003-05-23 | 2006-02-08 | Zentaris Gmbh | Novel pyridopyrazines and use thereof as kinase modulators. |
WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
AU2004259000A1 (en) | 2003-07-21 | 2005-02-03 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for PPAR |
CN1829709A (en) | 2003-08-01 | 2006-09-06 | 健亚生物科技公司 | Bicyclic imidazol derivatives against flaviviridae |
PT1673092E (en) | 2003-10-17 | 2007-11-23 | 4 Aza Ip Nv | Heterocycle-substituted pteridine derivatives and their use in therapy |
TWI347940B (en) | 2003-11-07 | 2011-09-01 | Novartis Ag | Methods for synthesizing quinolinone compounds |
WO2005054201A1 (en) | 2003-11-20 | 2005-06-16 | Janssen Pharmaceutica N.V. | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
WO2005054231A1 (en) | 2003-11-24 | 2005-06-16 | F.Hoffmann-La Roche Ag | Pyrazolyl and imidazolyl pyrimidines |
CA2548374C (en) | 2003-12-23 | 2014-05-27 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
CN101048388A (en) | 2004-08-31 | 2007-10-03 | 阿斯利康(瑞典)有限公司 | Quinazolinone derivatives and their use as B-Raf inhibitors |
KR20080075235A (en) | 2004-10-14 | 2008-08-14 | 에프. 호프만-라 로슈 아게 | 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity |
PL1830869T3 (en) | 2004-12-24 | 2013-11-29 | Novartis Ag | Method of treatment or prophylaxis |
US8278290B2 (en) | 2005-02-14 | 2012-10-02 | Biononics Limited | Tubulin polymerisation inhibitors |
WO2006092430A1 (en) | 2005-03-03 | 2006-09-08 | Universität des Saarlandes | Selective inhibitors of human corticosteroid synthases |
EP1881986A2 (en) | 2005-05-12 | 2008-01-30 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2006124944A1 (en) | 2005-05-18 | 2006-11-23 | Wyeth | 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same |
GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
BRPI0615233A2 (en) | 2005-08-26 | 2011-05-10 | Serono Lab | pyrazine derivatives and their use as p13k inhibitors |
AU2006313701B2 (en) | 2005-11-11 | 2012-05-31 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
EP1790342A1 (en) * | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazine derivatives and their use as signal transduction modulators |
MX2008008277A (en) | 2005-12-21 | 2009-03-04 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators. |
WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
GB0609621D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
US20100234347A1 (en) | 2006-05-24 | 2010-09-16 | Boehringer Ingelheim Internationl Gmbh | Substituted Pteridines substituted with a Four-Membered Heterocycle |
AU2007271187A1 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Fused bicyclic compounds interacting with the histamine H4 receptor |
JP2008127446A (en) | 2006-11-20 | 2008-06-05 | Canon Inc | 1,5-naphthyridine compound and organic light emitting device |
MX2009006466A (en) | 2006-12-13 | 2009-06-26 | Schering Corp | Methods of treatment. |
WO2008080001A2 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN101652352A (en) | 2006-12-22 | 2010-02-17 | 诺瓦提斯公司 | Quinazolines for PDK1 inhibition |
US8895745B2 (en) | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
KR20080062876A (en) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | Novel antifungal triazole derivatives |
EP1990342A1 (en) * | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
PE20090288A1 (en) | 2007-05-10 | 2009-04-03 | Smithkline Beecham Corp | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS |
WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
AR066879A1 (en) | 2007-06-08 | 2009-09-16 | Novartis Ag | DERIVATIVES OF QUINOXALINE AS INHIBITORS OF THE TYPOSINE CINASA ACTIVITY OF THE JANUS CINASES |
US8461209B2 (en) | 2007-06-20 | 2013-06-11 | Mitsubishi Tanabe Pharma Corporation | Malonic acid sulfonamide derivative and pharmaceutical use thereof |
JP5548123B2 (en) | 2007-06-21 | 2014-07-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Polymorphs and Hydration of 6- {Difluoro [6- (1-methyl-1H-pyrazol-4-yl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] methyl} quinoline Form, salt, and production method |
WO2009021083A1 (en) | 2007-08-09 | 2009-02-12 | Smithkline Beecham Corporation | Quinoxaline derivatives as pi3 kinase inhibitors |
WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
CA2704599C (en) | 2007-11-16 | 2015-05-12 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
WO2009137378A2 (en) | 2008-05-05 | 2009-11-12 | Schering Corporation | Sequential administration of chemotherapeutic agents for treatment of cancer |
CN102036963B (en) | 2008-05-23 | 2013-08-21 | 诺瓦提斯公司 | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
EP2356116A1 (en) | 2008-11-20 | 2011-08-17 | OSI Pharmaceuticals, Inc. | Substituted pyrroloý2,3-b¨-pyridines and-pyrazines |
CA2750047A1 (en) | 2009-01-21 | 2010-07-29 | Basilea Pharmaceutica Ag | Novel bicyclic antibiotics |
JP2012516847A (en) | 2009-02-02 | 2012-07-26 | メルク・シャープ・エンド・ドーム・コーポレイション | Inhibitor of AKT activity |
TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
DK2440545T3 (en) | 2009-06-12 | 2019-07-22 | Abivax | Compounds useful for treating cancer |
AU2010289397B2 (en) | 2009-09-03 | 2016-05-26 | Bioenergenix | Heterocyclic compounds for the inhibition of PASK |
WO2011026579A1 (en) | 2009-09-04 | 2011-03-10 | Bayer Schering Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
SG10201502484SA (en) | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
US8513421B2 (en) | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
US9096590B2 (en) | 2010-05-24 | 2015-08-04 | Intellikine Llc | Substituted benzoxazoles as PI3 kinase inhibitors |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
CN102532141A (en) | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | (1,2,4)-triazolo-(4,3-b) (1,2,4)-triazine compounds, as well as preparation method and use thereof |
AP2013007043A0 (en) | 2011-01-31 | 2013-08-31 | Novartis Ag | Novel heterocyclic derivatives |
TWI592411B (en) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | Combination of kinase inhibitors and uses thereof |
WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
ES2725790T3 (en) | 2011-08-26 | 2019-09-27 | Neupharma Inc | Some chemical entities, compositions, and methods |
AU2012308238B2 (en) | 2011-09-14 | 2017-05-25 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
EP2763994A4 (en) | 2011-10-04 | 2015-08-26 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
WO2013061305A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
JO3210B1 (en) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | Fused bicyclic oxazolidinone cetp inhibitor |
CN104379740B (en) | 2012-03-08 | 2019-05-14 | 安斯泰来制药株式会社 | Novel FGFR3 fusion |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
HUE053654T2 (en) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | Combinations of fgfr- and cmet-inhibitors for the treatment of cancer |
RU2715893C2 (en) | 2014-03-26 | 2020-03-04 | Астекс Терапьютикс Лтд | Combination of inhibitor fgfr and inhibitor igf1r |
JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
-
2011
- 2011-10-28 GB GBGB1118656.6A patent/GB201118656D0/en not_active Ceased
-
2012
- 2012-10-15 JO JOP/2012/0308A patent/JO3419B1/en active
- 2012-10-24 TW TW101139220A patent/TWI602814B/en active
- 2012-10-26 UY UY0001034418A patent/UY34418A/en active IP Right Grant
- 2012-10-26 MY MYPI2014001207A patent/MY185666A/en unknown
- 2012-10-26 SI SI201231385T patent/SI2776435T1/en unknown
- 2012-10-26 US US14/354,832 patent/US9309242B2/en active Active
- 2012-10-26 SG SG11201401055XA patent/SG11201401055XA/en unknown
- 2012-10-26 LT LTEP12794745.5T patent/LT2776435T/en unknown
- 2012-10-26 KR KR1020147010849A patent/KR102066496B1/en active IP Right Grant
- 2012-10-26 AU AU2012328170A patent/AU2012328170B2/en active Active
- 2012-10-26 EA EA201490891A patent/EA027563B1/en unknown
- 2012-10-26 MX MX2014004855A patent/MX353654B/en active IP Right Grant
- 2012-10-26 IN IN948MUN2014 patent/IN2014MN00948A/en unknown
- 2012-10-26 EP EP12794745.5A patent/EP2776435B1/en active Active
- 2012-10-26 BR BR112014010206A patent/BR112014010206B8/en active IP Right Grant
- 2012-10-26 WO PCT/GB2012/052672 patent/WO2013061080A1/en active Application Filing
- 2012-10-26 DK DK12794745.5T patent/DK2776435T3/en active
- 2012-10-26 CA CA2853390A patent/CA2853390C/en active Active
- 2012-10-26 AR ARP120104039A patent/AR088567A1/en active IP Right Grant
- 2012-10-26 AP AP2014007540A patent/AP4060A/en active
- 2012-10-26 UA UAA201405742A patent/UA111386C2/en unknown
- 2012-10-26 JP JP2014537730A patent/JP6169583B2/en active Active
- 2012-10-26 ES ES12794745.5T patent/ES2688868T3/en active Active
- 2012-10-26 CN CN201280065190.4A patent/CN104011051B/en active Active
-
2014
- 2014-04-10 IL IL232083A patent/IL232083B/en active IP Right Grant
- 2014-04-23 CO CO14086785A patent/CO6940422A2/en not_active Application Discontinuation
- 2014-04-25 CR CR20140190A patent/CR20140190A/en unknown
- 2014-04-25 NI NI201400032A patent/NI201400032A/en unknown
- 2014-04-25 CL CL2014001065A patent/CL2014001065A1/en unknown
- 2014-04-28 EC ECSP14013325 patent/ECSP14013325A/en unknown
-
2016
- 2016-02-09 US US15/019,563 patent/US10045982B2/en active Active
-
2018
- 2018-09-26 HR HRP20181533TT patent/HRP20181533T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN00948A (en) | ||
IN2014MN00987A (en) | ||
IN2014MN02049A (en) | ||
IN2014MN00986A (en) | ||
IN2012MN02591A (en) | ||
IN2014MN02069A (en) | ||
IN2014MN00988A (en) | ||
PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
MX2020010535A (en) | Methods of treating cancer. | |
TN2015000278A1 (en) | Autotaxin inhibitors | |
IL236221A (en) | Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases | |
EP2740796A4 (en) | Pharmaceutical composition for treatment and/or prophylaxis of cancer | |
PL2740794T3 (en) | Pharmaceutical composition for treatment and/or prophylaxis of cancer | |
HUE044611T2 (en) | Pharmaceutical composition for treatment of cancer | |
PL2824114T3 (en) | Pharmaceutical composition for treatment of cancer | |
PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
IL231926A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases and pharmaceutical compositions comprising them | |
MX349224B (en) | Pharmaceutical composition for use in the treatment of a neurodegenerative disease. | |
IN2014DN03010A (en) | ||
MX2016004094A (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide. | |
HK1157189A1 (en) | Pharmaceutical composition for the treatment of tumor diseases | |
AU2011900519A0 (en) | Drug compositions for the treatment of insomnia | |
HUP1100245A2 (en) | Pharmaceutical composition for the treatment of wounds |